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Research Article
High levels of healthcare utilization prior to diagnosis in
idiopathic pulmonary arterial hypertension support the
feasibility of an early diagnosis algorithm: the SPHInX project
Rito Bergemann1,2, James Allsopp3, Harvey Jenner4, Flora Ashley Daniels4, Edmund Drage4,
Yevgeniy Samyshkin1 , Claude Schmitt1, Steven Wood3,5, David G. Kiely5,6,7,* and
Allan Lawrie5,7,*, on behalf of the SPHInX Project team
1GlaxoSmithKline, Brentford, Middlesex, UK; 2Current affiliation: Evalueserve Life Sciences Healthcare, London, UK; 3Scientific Computing Group, Sheffield
Teaching Hospitals Foundation Trust, Sheffield, UK; 4IQVIA, London, UK; 5Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield,
Sheffield, UK; 6National Pulmonary Hypertension Service (Sheffield), Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, UK; 7INSIGNEO,
University of Sheffield, Sheffield, UK
Abstract
Idiopathic pulmonary arterial hypertension (iPAH) is a rare progressive, life-shortening disease, usually diagnosed at an advanced
stage. We hypothesize that patients with iPAH exhibit patterns of health-seeking behavior before diagnosis that will allow the
development of earlier identification tools. The Sheffield Pulmonary Hypertension IndeX (SPHInX) project aims to develop a
predictive algorithm based on routinely collected healthcare resource utilization (HCRU) data. This report focuses on the initial
feasibility of the project, examining whether Hospital Episode Statistics (HES) data from the National Health Service in England
have sufficient richness to support the development of an early diagnosis algorithm. This is a two-stage study. First, hospital
interactions during 2009–2014 captured in HES data identified 127,815 adult patients with pulmonary hypertension (PH) ICD-10
codes, containing a probable iPAH cohort with incidence and demographics similar to the reported literature. HCRU was high in
the three years before diagnosis. Second, to examine HCRU in patients with a confirmed iPAH diagnosis, we built the SPHInX
dataset incorporating all patients investigated for suspected PH in the Sheffield Pulmonary Vascular Disease Unit during 2008–2016
(n¼ 6674). For the SPHInX dataset, data could be linked to HES in 98.6% of cases and patients with confirmed iPAH had similar
levels of pre-diagnosis HCRU. In conclusion, patients with probable iPAH identified using HES and patients with confirmed iPAH
have high levels of HCRU for several years before diagnosis. Artificial intelligence models will now be used to develop the SPHInX
algorithm to screen for undiagnosed iPAH in the general population.
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Pulmonary arterial hypertension (PAH) is a rare, progres-
sive, and life-shortening condition that, untreated, leads to
right ventricular failure and death.1 It may be associated
with an underlying cause, but is often idiopathic
(iPAH).2,3 The prevalence and incidence of iPAH varies
by country and region and is reported to be 15–50 per
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million and 1.0–3.3 cases per million population per year,
respectively.3–5 At the time of diagnosis, iPAH is frequently
advanced, and untreated the median survival is <3 years.
While there is no cure for iPAH, treatments have evolved
over the past 10 years, resulting in improvements in symp-
toms, exercise capacity, hemodynamics, time to clinical wor-
sening, and/or survival.6
Symptoms of iPAH, such as breathlessness and fatigue,
are non-speciﬁc and the clinical signs are subtle until disease
is advanced.7 Diagnosis is usually ﬁrst suggested by echo-
cardiography and conﬁrmed by right heart catheterization
(RHC).6 Despite emerging evidence that early treatment is
associated with better outcomes,8–10 the typical delay
between the onset of symptoms to diagnosis of iPAH of
2–3 years has not improved in the past 20 years.11,12
Registry data conﬁrm that at the time of diagnosis, iPAH
is usually advanced from a hemodynamic perspective.13 In
patients with systemic sclerosis, the prevalence of PAH is
high (10%)14 and screening programs13,15–17 have been
shown to improve diagnostic rates and permit early detec-
tion of patients with less severe hemodynamic disease. While
screening is available in patients with systemic sclerosis to
identify PAH earlier due to its high prevalence,17–19 no such
approach is currently available for iPAH.
The goal of the overall Sheﬃeld Pulmonary Hypertension
IndeX (SPHInX) project is to develop a novel screening
algorithm to identify patients with iPAH at an early stage
of their disease. To date, no group has systematically looked
at healthcare activity before diagnosis to support early diag-
nosis of iPAH. We hypothesized that existing patient char-
acteristics, which can be accessed from coded entries in
national healthcare databases for hospital activity, have
the potential to facilitate early diagnosis of patients with
iPAH. To facilitate this, the ﬁrst phase of this project and
the focus of this manuscript was to determine whether rou-
tinely collected data obtained from the National Health
Service in England, captured in the Hospital Episode
Statistics (HES) dataset, has the potential to support the
development of a predictive algorithm for iPAH. In add-
ition, we also describe the development of the SPHInX
project.
Methods
Phase 1 – pilot study: exploring HES data to detect
patients with iPAH and assess their healthcare resource
use prior to diagnosis
Patients were identiﬁed from HES data obtained from
NHSE between April 2009 and October 2014. Figure 1a
shows the process used to select patients with iPAH.
International Statistical Classiﬁcation of Diseases and
Related Health Problems, version 10 (ICD-10) codes for
pulmonary hypertension (PH) (I27.0, I27.2, I27.9) were
used to identify potential patients with iPAH. Patients
were excluded if they: (1) did not undergo RHC; (2) did
not attend a specialist PH referral center; (3) had an
ICD-10 code for non-iPAH (Supplementary Table 1); (4)
were aged< 18 years or had attended the UK specialist
PH center for children at Great Ormond Street Hospital,
to yield the HES probable iPAH cohort. The annual inci-
dence of new probable iPAH diagnoses for each complete
year of data for 2010, 2011, 2012, and 2013, and the age and
gender distributions for the complete dataset, were deter-
mined. Annual incidence and age and gender distribution
of our probable iPAH cohort were compared to data
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Fig. 1. Patient flow in the pilot study. Dx, diagnosis; GOSH, Great Ormond Street Hospital; HES, Hospital Episodes Statistics; PH, pulmonary
hypertension; iPAH, idiopathic pulmonary arterial hypertension; SPVDU, Sheffield Pulmonary Vascular Disease Unit.
2 | Diagnosing iPAH earlier: an overview of the SPHInX project Bergemann et al.
available from the published literature from the UK,
France, and Switzerland.3,5,16,20
Following examination of the data within the HES prob-
able iPAH cohort, patients were further excluded if they: (5)
were diagnosed before April 2012 with< 3 years of HES
data available pre-diagnosis in the dataset (deﬁned by date
of RHC at one of the six specialist PH centers); (6) resided
outside England; or (7) had high healthcare resource utiliza-
tion (HCRU) 250 HES events, to ensure that within this
HES probable iPAH cohort, each patient was suitable for
the planned analysis. The mean number of hospital events,
as well as the frequency and type of specialties visited across
all care settings (accident and emergency [A&E], inpatient,
and outpatient) in the three years (Y3), two years (Y2), and
one year (Y1) before diagnosis with iPAH were calculated.
Phase 2: linking HES to Sheffield datasets
to build the SPHInX cohort
The Sheﬃeld Pulmonary Vascular Disease Unit (SPVDU)
and the University of Sheﬃeld have one of the largest iPAH-
enriched diagnostic clinical datasets in the world. Data from
three Sheﬃeld databases (ASPIRE Registry,13 InfoFlex
database containing operational clinical data including diag-
nostics and follow-up investigations, and the ArQ [Sheﬃeld
PH Biobank] database) were merged with data included
from December 2008 to October 2016 for 6674 unique
patients evaluated for suspected PH during this period.
Patients were linked to the HES dataset via their NHS
number to form the SPHInX database and patients with a
conﬁrmed iPAH diagnosis selected. This allowed us to build
a dataset comprising novel sources of real-world data
(national HES data, clinical data for all PAH patients
with suspected PH managed by Sheﬃeld Teaching
Hospitals NHS Foundation Trust [STHFT], and
University of Sheﬃeld/STHFT PH biobank data), subtype
patients who attend the Sheﬃeld center using clinical
experts’ validated data, and conﬁrm PAH diagnoses and
subtype. This would not be possible with HES data alone
due to the heterogeneous use of ICD-10 codes for iPAH.
Patient demographic characteristics (e.g. gender, month and
year of birth, and general practitioner postcode) were
assessed to ensure consistent linkage of patient data between
the SPHInX database and HES data.
Validation of first stage study findings using confirmed
iPAH diagnosis from the SPHInX database
Patients with conﬁrmed iPAH and HES data collected
between April 2000 and March 2017 (inpatient care: April
2000–March 2017; outpatient care: April 2003–March 2017;
A&E: April 2007–March 2017) were identiﬁed from the
SPHInX database. Patients were excluded if: (1) there was
no HES identiﬁer or demographic data did not match
between the SPHInX dataset and HES data; (2) they had
high HCRU with 250 HES events; or (3)< 3 years of data
before the index event were available (i.e. patients diagnosed
before April 2010) (Fig. 1b). From this linked SPHInX
cohort, we determined the: (1) index date, deﬁned as the
last relevant (cardiology, respiratory medicine, or neurology
specialist event) in their record before their ﬁrst visit to the
SPVDU (this is, on average, 76 days before their ﬁrst visit);
(2) lookback date, deﬁned as the earliest date of the patient’s
ﬁrst event captured in HES, or the event occurring ﬁve years
before the patient’s index date; (3) ﬁrst iPAH symptom,
deﬁned as the ﬁrst HES event assigned one of 141 ICD-10
and Classiﬁcation of Interventions and Procedures (OPCS)
codes in the primary diagnosis ﬁeld, derived from a blended
data and clinically driven approach for symptoms and pro-
cedures aligned to iPAH patients; and (4) patient’s ﬁrst
Sheﬃeld visit, based on the date of the patient’s ﬁrst visit
captured in the SPHInX datasets.
For patients with iPAH identiﬁed from the SPHInX
database, the mean number of hospital events, as well as
the frequency and type of specialties visited across all care
settings (A&E, inpatient, and outpatient), in years 1, 2, and
3 between lookback and index dates were calculated.
Ethical approval
An overview of the interdependency of data and details of
the ethical approvals required at each stage of the analyses
are shown in Supplementary Figure 1. Relevant permissions
and approvals were sought and obtained from the East
Midlands – Derby Research Ethics Committee (ref: 16/
EM/0286), and Conﬁdentiality Advisory Group (CAG),
for the linkage of datasets under Section 251 of the Health
and Social Care act 2014 (ref. no. 16CAG0091). The
Independent Group Advising on the Release of Data
(IGARD) at NHS Digital approved the use of HES data
for this study. The process to receive these permissions
required research approvals from the STHFT Caldicott
Guardian. We also sought and received a letter of support
for the research from the Pulmonary Hypertension
Association UK (PHA UK) patient advocacy group. Any
patient who had opted out of research was removed from
our analyses.
Results
Phase 1: identification of iPAH using HES data from
NHSE (pilot study)
Data extracted from HES between 2009 and 2014 identiﬁed
127,815 patients with an ICD-10 code for PH (I27.0, I27.2,
I27.9). Application of the selection criteria identiﬁed a
cohort of 589 patients with probable iPAH (Fig. 1a). This
corresponds to an incidence of 1.9/million in 2010, 2.0/mil-
lion in 2011, 1.7/million in 2012, and 1.9/million in 2013
(Fig. 2a). The incidence of probable iPAH diagnosed from
HES was within the range of reported incidences in the lit-
erature, which was in the range of 0.9–3.3/million per year.
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Similarly, for gender distribution, 60% of patients in the
HES dataset were women, compared to the published litera-
ture range of 62–70% (Fig. 2b). The age distribution of
patients identiﬁed from HES data was higher compared
with historical studies, with 64% aged> 50 years, although
this was similar to more recent series (Fig. 2c).
Phase 1: hospital-related activity identified from HES
before diagnosis of iPAH (pilot study)
Data for 218 patients with probable iPAH with at least three
years of data before diagnosis (April 2012 to October 2014)
(Fig. 1a) were analyzed and the mean number of hospital
events, as well as the frequency and type of specialties visited
across all care settings (A&E, inpatient, and outpatient), in
years 1, 2, and 3 before diagnosis are shown in Fig. 3. In the
three years before diagnosis, the average patient had
approximately 25 hospital events; 12 events were within
one year of RHC, of which six were with a cardiologist or
respiratory clinician. Most hospital events were outpatient
events, with an average of 20.2 per patient in the three years
before diagnosis, with 9.4 of these occurring in the year
before diagnosis; cardiology or thoracic events accounted
for approximately half (4.8 events in total). NHSE contact
within the three years before diagnosis encompassed an
average of 2.4 hospital trusts and six diﬀerent specialties
(data not shown).
Phase 2: building the SPHInX cohort with HES
The SPHInX dataset, which merged data from three separ-
ate databases, identiﬁed 6674 patients who were investigated
for suspected PH between 2008 and 2016, detecting 864
patients with conﬁrmed iPAH, 3944 patients with other
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forms of PH, and 1383 patients with no PH (483 patients
had no assigned ﬁnal diagnosis) and linked to HES data.
For patients with conﬁrmed iPAH, we were able to link
HES data for 852 out of 864 of these patients, representing
98.6% of all IPAH patients diagnosed with IPAH in
Sheﬃeld in this period of time.
Hospital-related activity identified from the SPHInX
database before index event (validation study)
Within the overall conﬁrmed iPAH cohort, 85% of patients
had recorded HES events dating back ﬁve years before the
index date. Among patients with conﬁrmed iPAH, their ﬁrst
symptom was recorded in General Medicine (36.0%),
Respiratory Medicine (32.8%), Cardiology (13.3%),
Geriatric Medicine (3.1%), Accident & Emergency (2.9%),
and General Surgery (1.1%). Data for 555 patients of the
SPHInX iPAH cohort having at least three years of data
before diagnosis (April 2010 to March 2017) were analyzed
and the mean number of hospital events, as well as the fre-
quency and type of specialties visited across all care settings
(A&E, inpatient, and outpatient), in years 1, 2, and 3 before
index date is shown in Fig. 4. In the three years before index
date, the average patient had approximately 23 hospital
events (Fig. 4a). Patients aged 50 years had more hospital
events in the three years before the index date than patients
aged< 50 years (Fig. 4b). Most hospital events were out-
patient events, with an average of 18.1 per patient in the
three years before the index date; cardiology or thoracic
events accounted for approximately 32.0%, with an average
of 5.8 total events during the three years before the index
date (Fig. 4c).
Discussion
In this study, we have demonstrated that patients with
probable iPAH can be identiﬁed from national databases
using ICD-10 codes with diagnostic rates similar to those
reported in various registries. Patients with probable iPAH
identiﬁed using this approach demonstrate high levels of
HCRU before diagnosis. We subsequently conﬁrmed these
ﬁndings in a carefully characterized cohort of patients with
conﬁrmed iPAH from the SPHInX database, and in doing
so demonstrate that patient level hospital data can be
linked to national HES data with high rates of success
(98.6%). The data available from routinely collected HES
have a richness and complexity that may potentially facili-
tate early diagnosis by identifying a ﬁngerprint to detect
patients at risk of iPAH. A model based on artiﬁcial
intelligence techniques will now be used to develop the
SPHInX algorithm; and if this demonstrates suﬃcient
diagnostic accuracy, we plan to deploy it in the general
healthcare user population to screen for patients with
undiagnosed iPAH.
The HES dataset has full population coverage of activity
for all patients accessing NHSE care, across outpatient,
inpatient, and A&E settings, and allows for descriptive ana-
lysis of patients. However, the dataset has several limita-
tions, including no speciﬁc ICD-10 code for iPAH, with
the code ‘‘primary pulmonary hypertension’’ often used to
diagnose patients with PAH, making it challenging to
explore HCRU in iPAH patients without the use of tech-
niques to further validate this cohort, multiple diﬀerent pul-
monary diseases being coded under the same ICD-10 code,
the absence of prescription data, and the collection of less
detail for patients entered in the A&E and outpatient set-
tings, compared with the inpatient setting. Nonetheless, we
consider the HES dataset used to identify patients with
iPAH to be robust based on the selected cohort and to cor-
relate well with the characteristics of patients with iPAH
described in the medical literature from the UK, France,
and Switzerland;3,5,16,20, however, we acknowledge that it
is likely to underdiagnose patients with iPAH and, indeed,
the annual incidence of iPAH from the SPHInX database
was several-fold higher. Nonetheless, it is interesting that
our iPAH cohort identiﬁed using HES data was very similar
demographically to those patients with a conﬁrmed diagno-
sis of iPAH from the SPHInX database who had similar
levels of activity pre-diagnosis (i.e. 17.7 events in the three
years before diagnosis and a similar proportion of patients
seeing respiratory and cardiology specialists). This high-
lights the opportunity to interrogate activity data from
HES to see if a ﬁngerprint can be identiﬁed, based on fre-
quency, type and temporal relationship of activities, that
may detect patients at risk of iPAH. While we believe the
opportunity here is considerable, the barriers to construct-
ing SPHINX have been substantial and may well have
meant that there are other conditions with similar charac-
teristics to iPAH where this approach could be beneﬁcial but
is unlikely to be undertaken. In particular, the duration of
time (17þ months) to secure the relevant permissions for the
varies bodies and obtain the required data is a substantial
challenge in pursuing this type or research.
Screening is advocated for several conditions to facilitate
early diagnosis. However, while screening can improve
patient outcomes, it may also be detrimental; several factors
must be carefully considered when contemplating screening
initiatives to safeguard patients. Screening must have the
likelihood of improving long-term outcomes for patients;
it must have a minimal risk of falsely identifying healthy
individuals or over diagnosing the disease. The economic
impact of the screening and any subsequent interventions
must also be carefully weighed. Currently within NHSE, a
number of screening programs exist to facilitate early diag-
nosis of cancer and to identify patients at risk of cardiovas-
cular events, where early treatment may result in cure or
strategies may reduce the development of vascular compli-
cations.21 PAH is a challenging condition to diagnose due to
the non-speciﬁcity of symptoms and the invasive nature of
tests required to conﬁrm its presence. Consequently,
patients tend to present when the disease is advanced.
The population can be enriched for patients at risk of
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developing PAH, such as in systemic sclerosis where screen-
ing is advocated in asymptomatic patients due to its high
prevalence (10%), or in symptomatic patients with portal
hypertension or human immunodeﬁciency virus infection,
where the prevalence is lower compared with systemic scler-
osis (but still signiﬁcantly higher versus the general popula-
tion). Strategies to try and diagnose patients with iPAH at
an earlier stage of disease have focused on increasing disease
awareness and a systematic approach to the investigation of
the breathless patient, in the hope that this will facilitate
improved diagnostic rates. The results for iPAH, however,
remain very disappointing with the eﬀorts of the last 20
years achieving no reduction in time from initial iPAH
symptom to diagnosis, and with the majority of patients
still presenting with advanced disease in World Health
Organization functional class III and IV. The emergence
of large and complex datasets describing healthcare behav-
ior, and the development of approaches to allow them to be
analyzed using machine-learning techniques, provide us
with an opportunity to explore novel methods to identify
patients with iPAH.
This study found high levels of activity and frequent con-
tacts with healthcare services in the three years before a
conﬁrmed diagnosis of iPAH. In addition, patients fre-
quently attended respiratory and cardiology specialties.
The combination of high levels of activity and the richness
of specialty interactions raises the possibility that patients
with iPAH may exhibit characteristic patterns of behavior
separate from other cardiorespiratory conditions, providing
suﬃcient data to support the development of a predictive
diagnostic algorithm for iPAH.
We are currently engaged in a big-data approach, utiliz-
ing a model based on artiﬁcial intelligence to develop a pre-
dictive algorithm to screen for patients with undiagnosed
iPAH in the general population.
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